Akebia Therapeutics Q3 EPS $(0.05) Misses $(0.04) Estimate, Sales $36.900M Miss $46.941M Estimate
Benzinga Newsdesk 23 hours ago
NewsEarningsEarnings Misses
Akebia Therapeutics (NASDAQ:AKBA) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $(0.04) by 25 percent. The company reported quarterly sales of $36.900 million which
Akebia Therapeutics (NASDAQ:AKBA) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $(0.04) by 25 percent. The company reported quarterly sales of $36.900 million which missed the analyst consensus estimate of $46.941 million by 21.39 percent. This is a 37.21 percent decrease over sales of $58.766 million the same period last year.